17.01.2014 Views

Download the PDF version here - Indo-American Chamber Of ...

Download the PDF version here - Indo-American Chamber Of ...

Download the PDF version here - Indo-American Chamber Of ...

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

solution leverages IBM’s Intelligent Building Management (IIBM) system (a combination of monitoring,<br />

asset management and advanced analytics) along with Ingersoll Rand’s Energy optimization<br />

technologies, to help trigger preventive and predictive maintenance to create smarter buildings,<br />

according to an IBM statement.<br />

Buildings in India account for 30 per cent of energy consumption. <strong>Of</strong> this consumption, <strong>the</strong> major usage<br />

is due to HVAC (heating, ventilating and air-conditioning) and lighting. As <strong>the</strong> Indian economy develops<br />

and commercial infrastructure gets built, it becomes essential to drive robust initiatives to improve<br />

energy efficiency and sustainability. In <strong>the</strong> current economic scenario, with rising energy costs,<br />

organizations are facing capital and operating budget challenges. Maximizing capital productivity<br />

requires increasing asset utilization, efficiency and uptime. Similarly, <strong>the</strong> operating costs of energy and<br />

maintenance need to be optimized, IBM said.<br />

Mr. Venkatesh Valluri, Chairman & President, Ingersoll Rand India said, “Ingersoll Rand has been at <strong>the</strong><br />

forefront of driving ‘Innovation and Technology Convergence’ and to us this means bringing toge<strong>the</strong>r<br />

organizations and technologies on a common platform and converging <strong>the</strong>m to drive profitable<br />

sustainability practices. This partnership is a strategic initiative w<strong>here</strong> IBM and Ingersoll Rand are<br />

combining <strong>the</strong>ir strengths in operations and management systems to bring end-to-end managed<br />

services to customers.” “This partnership with Ingersoll Rand reaffirms our commitment by using<br />

intelligent data to build smarter buildings that are accountable for energy and carbon resource use,<br />

helping create a sustainable environment,” said Mr. Nipun Mehrotra, Vice-President & General<br />

Manager, Sales & Business Development, IBM India/South Asia.<br />

Click <strong>here</strong> for index<br />

Microsoft partners Morpheus, Accel to help startups in India<br />

Software giant Microsoft has partnered with Morpheus and Accel in <strong>the</strong> country to provide support and<br />

services to startup companies, helping <strong>the</strong>m grow <strong>the</strong>ir business.<br />

BizSpark Plus, an extension of <strong>the</strong> earlier BizSpark program, works through incubators and accelerators<br />

to provide value added products and services to high potential startups.<br />

Morpheus and Accel have been appointed accelerators in India, and working through <strong>the</strong>m, <strong>the</strong> program<br />

will offer each of <strong>the</strong>ir startups up to USD 60,000 of Windows Azure services over a 24-month period to<br />

help develop <strong>the</strong>ir ideas and solutions.<br />

Click <strong>here</strong> for index<br />

Indian drug companies, hit US jackpot in December quarter<br />

Five of India’s top 10 pharma firms collectively raked in <strong>the</strong>ir best quarterly revenues in <strong>the</strong> US in<br />

October-December. During this period, total US earnings of Ranbaxy Labs, Dr. Reddy’s, Sun Pharma,<br />

Lupin and Zydus Cadila almost touched Rs. 5,000 crore. This is 80% of what Ranbaxy, Dr. Reddy’s, Lupin<br />

and Cadila cumulatively earn from <strong>the</strong>ir domestic business every year.<br />

Excluding Lupin, which operates in both patented and generic drugs business in <strong>the</strong> US, combined<br />

quarterly earnings of <strong>the</strong> four firms, grew 112% during <strong>the</strong> quarter on an annual basis. The timing, when<br />

several blockbuster drugs with market size over $1billion were losing patent protection, proved<br />

fortunate for many of <strong>the</strong>se firms. The surge in US business comes at a time when many of <strong>the</strong>se<br />

companies feel “irrational” price controls and emerging patent regime are undermining <strong>the</strong>ir growth<br />

potential within <strong>the</strong> country.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!